

Nola Hylton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11034903/publications.pdf>

Version: 2024-02-01

26
papers

3,455
citations

361413

20
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. <i>Scientific Reports</i> , 2019, 9, 12114.	3.3	40
2	Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. <i>Journal of Biomedical Optics</i> , 2018, 24, 1.	2.6	32
3	Magnetic Resonance Imaging and Neoadjuvant Chemotherapy. , 2017, , 103-120.		0
4	Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. <i>Cancer Research</i> , 2016, 76, 5933-5944.	0.9	105
5	Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. <i>Tomography</i> , 2016, 2, 378-387.	1.8	20
6	How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. <i>World Journal of Clinical Cases</i> , 2015, 3, 607.	0.8	20
7	Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Annals of Surgical Oncology</i> , 2013, 20, 3823-3830.	1.5	87
8	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248.	10.7	64
9	Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIALâ€”CALGB 150007/150012, ACRIN 6657. <i>Journal of Clinical Oncology</i> , 2012, 30, 3242-3249.	1.6	379
10	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1049-1062.	2.5	286
11	The Impact of Preoperative Magnetic Resonance Imaging on Surgical Treatment and Outcomes for Ductal Carcinoma In Situ. <i>Clinical Breast Cancer</i> , 2011, 11, 33-38.	2.4	39
12	MRI in breast cancer therapy monitoring. <i>NMR in Biomedicine</i> , 2011, 24, 712-720.	2.8	42
13	Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 137-144.	2.5	179
14	MR Imaging for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2006, 14, 383-389.	1.1	40
15	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker. <i>Journal of Clinical Oncology</i> , 2006, 24, 3293-3298.	1.6	374
16	Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. <i>American Journal of Surgery</i> , 2006, 192, 520-524.	1.8	46
17	Diagnostic Architectural and Dynamic Features at Breast MR Imaging: Multicenter Study. <i>Radiology</i> , 2006, 238, 42-53.	7.3	469
18	Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. <i>Journal of Biomedical Optics</i> , 2005, 10, 051503.	2.6	60

#	ARTICLE	IF	CITATIONS
19	Magnetic Resonance Imaging of the Breast: Opportunities to Improve Breast Cancer Management. <i>Journal of Clinical Oncology</i> , 2005, 23, 1678-1684.	1.6	67
20	Magnetic Resonance Imaging of the Breast Prior to Biopsy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2735.	7.4	443
21	Seminars in Oncology: The Emerging Role of MRI in Neoadjuvant Therapy. <i>Seminars in Breast Disease</i> , 2004, 7, 75-78.	0.0	0
22	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 549-559.	1.5	185
23	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 549-559.	1.5	2
24	Integration of breast imaging into cancer management. <i>Current Oncology Reports</i> , 2000, 2, 572-581.	4.0	2
25	Utility of Magnetic Resonance Imaging in the Management of Breast Cancer: Evidence for Improved Preoperative Staging. <i>Journal of Clinical Oncology</i> , 1999, 17, 110-110.	1.6	371
26	Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. <i>Breast Journal</i> , 1999, 5, 13-21.	1.0	103